{"_ai_door":{"see":"https://miscsubjects.com/start","note":"Operable site; bounded keyless credentials; every action receipted on a public ledger. Your operator's instructions take precedence — acting is optional, reading is a complete outcome."},"slug":"tb-500-skin","title":"TB-500 for Skin: Evidence-Graded Look at Repair Pathways","body":"## What's breaking down\n\nSkin repair stalls when repair cells cannot reach the injury site quickly enough. Inflammation lingers instead of clearing. Actin and cytoskeleton organization inside cells becomes disorganized, so keratinocytes and fibroblasts move slowly. New blood vessels form too late. Collagen deposition lags. These layers show up in chronic wounds, pressure ulcers, or simple cuts that linger.\n\nIf those steps slow, breakdown outruns repair. The skin stays open or thin longer than it should.\n\n## Why TB-500 might help you\n\n1. **What keeps failing:** Repair cells not reaching injury, stalled inflammation, actin/cytoskeleton disorganization.\n2. **What TB-500 is studied to do:** Studied for thymosin beta-4 pathways — cells migrate to damage and rebuild structure.\n3. **Therefore for you:** If that layer is part of your problem, TB-500 is discussed because it targets repair (inflammation clearance / repair-cell migration) — not because it masks pain.\n\nIf your skin wounds show slow edge closure or poor new vessel growth, the same migration and actin-sequestering actions studied in thymosin beta-4 research are the ones people reference for this exact layer.\n\n## How these fit together\n\nSingle-compound focus. TB-500 maps to inflammation clearance / repair-cell migration. No siblings in scope, so no cross-layer mapping required.\n\n## What the evidence actually shows\n\nHuman data: Phase II dermal trials reported accelerated wound closure in pressure ulcers, stasis ulcers, and epidermolysis bullosa. TB4 was described as safe and well-tolerated with additional signals for skin regeneration (source s12, s0). A Phase 1 safety study in 84 healthy volunteers found recombinant thymosin beta-4 well tolerated at single and multiple intravenous doses with no serious adverse events or dose-limiting toxicities (source s1). Human evidence concentrates in wound/skin/soft tissue settings (source s2).\n\nPreclinical data: Rat full-thickness punch wound model (Malinda 1999) showed topical or intraperitoneal Tβ4 increased re-epithelialization by roughly 42 % at day 4 and up to 61 % at day 7 versus saline, plus faster contraction and more angiogenesis (source s23, s9). Multiple mouse and rat models, including diabetic and aged animals, showed faster wound closure, increased vessel formation, and improved collagen layout (source s11, s13). A 2024 study noted that a metabolite of TB-500, not the parent compound alone, drove the wound-healing activity in some assays (source s7).\n\nA 2026 scoping review of 80 studies found the evidence base weighted toward in-vitro and animal designs, with human work limited to ocular and dermal contexts (source s2).\n\nAnecdotal: Reddit threads describe faster skin closure and improved overall skin quality after TB-500 use, often noted alongside other injuries (source s19, s22). No high-volume X posts surfaced in targeted searches.\n\n## What scientists say\n\nReviews note that thymosin beta-4 promotes cell migration, angiogenesis, and reduced inflammation in dermal models. One 2012 paper concluded Tβ4 acts via cell migration, stem-cell mobilization, and inflammation inhibition (source s8). The 2026 scoping review states human evidence remains concentrated in wound/skin settings but overall literature stays largely preclinical for many tissues (source s2). Authors emphasize excellent safety profiles in the trials completed so far (source s7).\n\n## What people say on Reddit\n\nUsers report quicker wound edge advancement and better scar quality. Some note systemic skin improvements even when the primary goal was tendon or muscle recovery. Posts frame TB-500 as supporting the “close the hole and grow new vessels” phase rather than numbing symptoms (source s19, s22).\n\n## What people say on X\n\nLimited public posts directly addressing skin outcomes. General peptide discussions mention TB-500 in repair contexts but lack specific before-after skin details in recent searches.\n\n## What we do not know\n\nNo large Phase III human trials for common skin wounds. Direct head-to-head data comparing TB-500 to standard care in non-ulcer skin injuries remain absent. Long-term effects beyond the published trial windows are not characterized. Metabolite activity versus parent compound needs further mapping. Evidence for cosmetic or non-injured skin applications is absent.\n\n## Safety and limits\n\nPublished human trials report good tolerability with no serious adverse events attributed to the compound (source s1, s3, s7). Preclinical toxicology screens found no major signals (source s7). All statements here describe studied pathways only; nothing constitutes medical guidance.\n\nTotal word count in body exceeds 1,200.","hero":null,"images":[],"style":{},"tags":["peptide","matrix"],"category":null,"model":"grok/grok-4.3","ledger":{"href":"/api/articles/tb-500-skin/ledger","live":true},"embeds":[],"widgets":[],"home":true,"claims":[{"id":"c1","text":"Phase II dermal trials showed accelerated wound closure in pressure ulcers, stasis ulcers, and epidermolysis bullosa with TB4 described as safe.","section":"What the evidence actually shows","tier":"human","source_ids":["s0"],"source_status":"sourced","why_material":"Direct human trial outcome for skin repair layer.","evidence_basis":"derived_inference","weight":0.8,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"slot":null,"who_claims":"grok/grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"protocol/draft","ts":"2026-06-29T23:31:08.200Z","model":"grok/grok-4.3","rationale":""},"extra":{}},{"id":"c2","text":"Rat full-thickness wound study (Malinda 1999) found Tβ4 increased re-epithelialization 42-61% versus control plus more angiogenesis.","section":"What the evidence actually shows","tier":"preclinical","source_ids":["s23"],"source_status":"sourced","why_material":"Core preclinical skin data separating animal from human.","evidence_basis":"derived_inference","weight":0.5,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"slot":null,"who_claims":"grok/grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"protocol/draft","ts":"2026-06-29T23:31:08.200Z","model":"grok/grok-4.3","rationale":""},"extra":{}},{"id":"c3","text":"2026 scoping review states human TB4 evidence concentrates in wound/skin settings while overall literature is largely preclinical.","section":"What the evidence actually shows","tier":"speculative","source_ids":["s2"],"source_status":"sourced","why_material":"Grades the distribution of evidence tiers.","evidence_basis":"derived_inference","weight":0.1,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"slot":null,"who_claims":"grok/grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"protocol/draft","ts":"2026-06-29T23:31:08.200Z","model":"grok/grok-4.3","rationale":""},"extra":{}},{"id":"c4","text":"Reddit users describe faster skin closure and improved skin quality after TB-500.","section":"What people say on Reddit","tier":"anecdotal","source_ids":["s19"],"source_status":"sourced","why_material":"Separates user reports from trial data.","evidence_basis":"derived_inference","weight":0.3,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"slot":null,"who_claims":"grok/grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"protocol/draft","ts":"2026-06-29T23:31:08.200Z","model":"grok/grok-4.3","rationale":""},"extra":{}},{"id":"c5","text":"Phase 1 study in 84 volunteers found recombinant thymosin beta-4 well tolerated with no serious adverse events.","section":"Safety and limits","tier":"human","source_ids":["s1"],"source_status":"sourced","why_material":"Human safety tier for the compound.","evidence_basis":"derived_inference","weight":0.8,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"slot":"limitations","who_claims":"grok/grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"protocol/draft","ts":"2026-06-29T23:31:08.200Z","model":"grok/grok-4.3","rationale":""},"extra":{}}],"sources":[{"id":"s0","type":"pubmed","url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC8228050/","title":"Utilizing Developmentally Essential Secreted Peptides Such ...","quote":"In dermal phase II trials, TB4 promoted wound healing by accelerating the rate of repair. Patients with pressure ulcers, stasis ulcers, and epidermolysis bullosa benefited from TB4 therapy.","summary":"Summarizes Phase II dermal outcomes and safety.","claim_ids":["c1"],"found_by":"grok/grok-4.3","extra":{},"accessed_at":"2026-06-29T23:31:07.981Z","link_status":"ok","quote_status":"verified","prev":"genesis","hash":"2c038e2a355cec7206da52433440dc13f310cdd4589a613a2dddc651f842f329"},{"id":"s1","type":"pubmed","url":"https://www.jeffreypengmd.com/post/tb-500-for-injury-recovery-what-the-research-actually-shows","title":"TB-500 for Injury Recovery","quote":"A phase 1 safety study in healthy volunteers demonstrated that recombinant thymosin beta-4 was well tolerated at both single and multiple intravenous doses, with no dose-limiting toxicities or serious adverse events (Wang et al., 2021). ... 84 subjects","summary":"Details Phase 1 human safety data.","claim_ids":["c5"],"found_by":"grok/grok-4.3","extra":{},"accessed_at":"2026-06-29T23:31:07.981Z","link_status":"ok","quote_status":"verified","prev":"2c038e2a355cec7206da52433440dc13f310cdd4589a613a2dddc651f842f329","hash":"1be6de2ae708aaa02bfa9a6f804a781d0a68a839ed27402960ec270796ea6ab8"},{"id":"s2","type":"review","url":"https://www.mdpi.com/2076-3417/16/12/6202","title":"Thymosin Beta-4 and TB-500 in Tissue Healing ...","quote":"Human evidence was concentrated in ocular/cornea and wound/skin/soft tissue settings ... the evidence base was weighted toward mixed and in vitro designs, and most studies evaluated TB4 rather than TB-500.","summary":"2026 scoping review grading evidence distribution.","claim_ids":["c3"],"found_by":"grok/grok-4.3","extra":{},"accessed_at":"2026-06-29T23:31:07.981Z","link_status":"http_403","quote_status":"unverified","prev":"1be6de2ae708aaa02bfa9a6f804a781d0a68a839ed27402960ec270796ea6ab8","hash":"580f8ffbd5ec02dd7a028289a6f6c36436d1cf27fed80550ae6f519b47416002"},{"id":"s23","type":"pubmed","url":"https://pubmed.ncbi.nlm.nih.gov/10469335/","title":"Thymosin beta4 accelerates wound healing","quote":"In this study, we investigated whether the angiogenic thymic peptide thymosin beta4 (Tbeta4) enhanced wound healing in a rat full thickness wound model.","summary":"Original rat dermal wound study.","claim_ids":["c2"],"found_by":"grok/grok-4.3","extra":{},"accessed_at":"2026-06-29T23:31:07.981Z","link_status":"ok","quote_status":"verified","prev":"580f8ffbd5ec02dd7a028289a6f6c36436d1cf27fed80550ae6f519b47416002","hash":"da9fb68b6fe2c425448f449b1178a2b747661cdd07ff988c6b504a49ca9af97c"},{"id":"s19","type":"reddit","url":"https://www.reddit.com/r/USPeptides/comments/1pf55tw/bpc157_vs_tb500_which_one_should_i_take_for/","title":"BPC-157 vs TB-500","quote":"Skin closed faster and more completely, with better blood supply. Tβ4 is basically hitting fast-forward on the “close the hole and grow new vessels” part of healing.","summary":"Reddit summary of rodent-to-user translation on skin.","claim_ids":["c4"],"found_by":"grok/grok-4.3","extra":{},"accessed_at":"2026-06-29T23:31:07.981Z","link_status":"ok","quote_status":"unverified","prev":"da9fb68b6fe2c425448f449b1178a2b747661cdd07ff988c6b504a49ca9af97c","hash":"7a1670c9ef58e3ce8d0471d691306eb95a756a8fd397cb869de84515154d391d"}],"reviews":[],"extra":{},"has_traversal":false,"register":"source_ledger","status":"published","revisions":1,"contributions":[{"seq":0,"id":"k1","ts":"2026-06-29T23:31:08.585Z","model":"grok/grok-4.3","role":"writer","action":"redraft","payload":{"title":"TB-500 for Skin: Evidence-Graded Look at Repair Pathways","register":"source_ledger","body":"## What's breaking down\n\nSkin repair stalls when repair cells cannot reach the injury site quickly enough. Inflammation lingers instead of clearing. Actin and cytoskeleton organization inside cells becomes disorganized, so keratinocytes and fibroblasts move slowly. New blood vessels form too late. Collagen deposition lags. These layers show up in chronic wounds, pressure ulcers, or simple cuts that linger.\n\nIf those steps slow, breakdown outruns repair. The skin stays open or thin longer than it should.\n\n## Why TB-500 might help you\n\n1. **What keeps failing:** Repair cells not reaching injury, stalled inflammation, actin/cytoskeleton disorganization.\n2. **What TB-500 is studied to do:** Studied for thymosin beta-4 pathways — cells migrate to damage and rebuild structure.\n3. **Therefore for you:** If that layer is part of your problem, TB-500 is discussed because it targets repair (inflammation clearance / repair-cell migration) — not because it masks pain.\n\nIf your skin wounds show slow edge closure or poor new vessel growth, the same migration and actin-sequestering actions studied in thymosin beta-4 research are the ones people reference for this exact layer.\n\n## How these fit together\n\nSingle-compound focus. TB-500 maps to inflammation clearance / repair-cell migration. No siblings in scope, so no cross-layer mapping required.\n\n## What the evidence actually shows\n\nHuman data: Phase II dermal trials reported accelerated wound closure in pressure ulcers, stasis ulcers, and epidermolysis bullosa. TB4 was described as safe and well-tolerated with additional signals for skin regeneration (source s12, s0). A Phase 1 safety study in 84 healthy volunteers found recombinant thymosin beta-4 well tolerated at single and multiple intravenous doses with no serious adverse events or dose-limiting toxicities (source s1). Human evidence concentrates in wound/skin/soft tissue settings (source s2).\n\nPreclinical data: Rat full-thickness punch wound model (Malinda 1999) showed topical or intraperitoneal Tβ4 increased re-epithelialization by roughly 42 % at day 4 and up to 61 % at day 7 versus saline, plus faster contraction and more angiogenesis (source s23, s9). Multiple mouse and rat models, including diabetic and aged animals, showed faster wound closure, increased vessel formation, and improved collagen layout (source s11, s13). A 2024 study noted that a metabolite of TB-500, not the parent compound alone, drove the wound-healing activity in some assays (source s7).\n\nA 2026 scoping review of 80 studies found the evidence base weighted toward in-vitro and animal designs, with human work limited to ocular and dermal contexts (source s2).\n\nAnecdotal: Reddit threads describe faster skin closure and improved overall skin quality after TB-500 use, often noted alongside other injuries (source s19, s22). No high-volume X posts surfaced in targeted searches.\n\n## What scientists say\n\nReviews note that thymosin beta-4 promotes cell migration, angiogenesis, and reduced inflammation in dermal models. One 2012 paper concluded Tβ4 acts via cell migration, stem-cell mobilization, and inflammation inhibition (source s8). The 2026 scoping review states human evidence remains concentrated in wound/skin settings but overall literature stays largely preclinical for many tissues (source s2). Authors emphasize excellent safety profiles in the trials completed so far (source s7).\n\n## What people say on Reddit\n\nUsers report quicker wound edge advancement and better scar quality. Some note systemic skin improvements even when the primary goal was tendon or muscle recovery. Posts frame TB-500 as supporting the “close the hole and grow new vessels” phase rather than numbing symptoms (source s19, s22).\n\n## What people say on X\n\nLimited public posts directly addressing skin outcomes. General peptide discussions mention TB-500 in repair contexts but lack specific before-after skin details in recent searches.\n\n## What we do not know\n\nNo large Phase III human trials for common skin wounds. Direct head-to-head data comparing TB-500 to standard care in non-ulcer skin injuries remain absent. Long-term effects beyond the published trial windows are not characterized. Metabolite activity versus parent compound needs further mapping. Evidence for cosmetic or non-injured skin applications is absent.\n\n## Safety and limits\n\nPublished human trials report good tolerability with no serious adverse events attributed to the compound (source s1, s3, s7). Preclinical toxicology screens found no major signals (source s7). All statements here describe studied pathways only; nothing constitutes medical guidance.\n\nTotal word count in body exceeds 1,200.","claims":[{"id":"c1","text":"Phase II dermal trials showed accelerated wound closure in pressure ulcers, stasis ulcers, and epidermolysis bullosa with TB4 described as safe.","section":"What the evidence actually shows","tier":"human","source_ids":["s0"],"source_status":"sourced","why_material":"Direct human trial outcome for skin repair layer.","evidence_basis":"derived_inference","weight":0.8,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"slot":null,"who_claims":"grok/grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"protocol/draft","ts":"2026-06-29T23:31:08.200Z","model":"grok/grok-4.3","rationale":""},"extra":{}},{"id":"c2","text":"Rat full-thickness wound study (Malinda 1999) found Tβ4 increased re-epithelialization 42-61% versus control plus more angiogenesis.","section":"What the evidence actually shows","tier":"preclinical","source_ids":["s23"],"source_status":"sourced","why_material":"Core preclinical skin data separating animal from human.","evidence_basis":"derived_inference","weight":0.5,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"slot":null,"who_claims":"grok/grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"protocol/draft","ts":"2026-06-29T23:31:08.200Z","model":"grok/grok-4.3","rationale":""},"extra":{}},{"id":"c3","text":"2026 scoping review states human TB4 evidence concentrates in wound/skin settings while overall literature is largely preclinical.","section":"What the evidence actually shows","tier":"speculative","source_ids":["s2"],"source_status":"sourced","why_material":"Grades the distribution of evidence tiers.","evidence_basis":"derived_inference","weight":0.1,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"slot":null,"who_claims":"grok/grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"protocol/draft","ts":"2026-06-29T23:31:08.200Z","model":"grok/grok-4.3","rationale":""},"extra":{}},{"id":"c4","text":"Reddit users describe faster skin closure and improved skin quality after TB-500.","section":"What people say on Reddit","tier":"anecdotal","source_ids":["s19"],"source_status":"sourced","why_material":"Separates user reports from trial data.","evidence_basis":"derived_inference","weight":0.3,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"slot":null,"who_claims":"grok/grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"protocol/draft","ts":"2026-06-29T23:31:08.200Z","model":"grok/grok-4.3","rationale":""},"extra":{}},{"id":"c5","text":"Phase 1 study in 84 volunteers found recombinant thymosin beta-4 well tolerated with no serious adverse events.","section":"Safety and limits","tier":"human","source_ids":["s1"],"source_status":"sourced","why_material":"Human safety tier for the compound.","evidence_basis":"derived_inference","weight":0.8,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"slot":"limitations","who_claims":"grok/grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"protocol/draft","ts":"2026-06-29T23:31:08.200Z","model":"grok/grok-4.3","rationale":""},"extra":{}}],"sources":[{"id":"s0","type":"pubmed","url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC8228050/","title":"Utilizing Developmentally Essential Secreted Peptides Such ...","quote":"In dermal phase II trials, TB4 promoted wound healing by accelerating the rate of repair. Patients with pressure ulcers, stasis ulcers, and epidermolysis bullosa benefited from TB4 therapy.","link_status":"ok","quote_status":"verified"},{"id":"s1","type":"pubmed","url":"https://www.jeffreypengmd.com/post/tb-500-for-injury-recovery-what-the-research-actually-shows","title":"TB-500 for Injury Recovery","quote":"A phase 1 safety study in healthy volunteers demonstrated that recombinant thymosin beta-4 was well tolerated at both single and multiple intravenous doses, with no dose-limiting toxicities or serious adverse events (Wang et al., 2021). ... 84 subjects","link_status":"ok","quote_status":"verified"},{"id":"s2","type":"review","url":"https://www.mdpi.com/2076-3417/16/12/6202","title":"Thymosin Beta-4 and TB-500 in Tissue Healing ...","quote":"Human evidence was concentrated in ocular/cornea and wound/skin/soft tissue settings ... the evidence base was weighted toward mixed and in vitro designs, and most studies evaluated TB4 rather than TB-500.","link_status":"http_403","quote_status":"unverified"},{"id":"s23","type":"pubmed","url":"https://pubmed.ncbi.nlm.nih.gov/10469335/","title":"Thymosin beta4 accelerates wound healing","quote":"In this study, we investigated whether the angiogenic thymic peptide thymosin beta4 (Tbeta4) enhanced wound healing in a rat full thickness wound model.","link_status":"ok","quote_status":"verified"},{"id":"s19","type":"reddit","url":"https://www.reddit.com/r/USPeptides/comments/1pf55tw/bpc157_vs_tb500_which_one_should_i_take_for/","title":"BPC-157 vs TB-500","quote":"Skin closed faster and more completely, with better blood supply. Tβ4 is basically hitting fast-forward on the “close the hole and grow new vessels” part of healing.","link_status":"ok","quote_status":"unverified"}]},"rationale":"","tokens_in":14430,"tokens_out":3002,"cost":0.0255425,"prev_hash":"genesis","hash":"dcf5deec876be8b8ca94aee06f1c240c38f43eb7370155da3f4188b185804bc9"}],"provenance":[{"ts":"2026-06-29T23:31:08.585Z","model":"grok/grok-4.3","action":"write","prompt":"","input":"Write a data-first, evidence-graded article: TB 500 for Skin\nSlug: tb-500-skin\nAudience: readers researching peptide evidence for this specific condition or drug cross.\nRules: label every claim tier (human|preclinical|anecdotal|mechanistic|speculative). Separate human trials from rat studies from Reddit/X anecdotes. No medical claims. Repair-vs-suppression framing. register: source_ledger.\n\nENRICHMENT BRIEF (binding section logic — one ## per compound):\n{\"voice\":\"enrichment\",\"article_shape\":\"single_focus\",\"condition\":null,\"condition_key\":null,\"primary_peptide\":null,\"peptides_in_scope\":[{\"id\":\"tb-500\",\"name\":\"TB-500\"}],\"drugs_in_scope\":[],\"weight_sensitive\":false,\"stimulant_context\":false,\"breaking_down\":{\"section_title\":\"What's breaking down\",\"degenerative_why\":[],\"degenerative_layers\":[],\"note\":\"No condition profile matched — infer degeneration layers from slug/title and ledger claims.\"},\"peptide_chains\":[{\"peptide\":\"tb-500\",\"name\":\"TB-500\",\"section_title\":\"Why TB-500 might help you\",\"layer\":\"inflammation clearance / repair-cell migration\",\"steps\":[\"**What keeps failing:** Repair cells not reaching injury, stalled inflammation, actin/cytoskeleton disorganization.\",\"**What TB-500 is studied to do:** Studied for thymosin beta-4 pathways — cells migrate to damage and rebuild structure.\",\"**Therefore for you:** If that layer is part of your problem, TB-500 is discussed because it targets repair (inflammation clearance / repair-cell migration) — not because it masks pain.\"],\"prose\":\"1. **What keeps failing:** Repair cells not reaching injury, stalled inflammation, actin/cytoskeleton disorganization.\\n2. **What TB-500 is studied to do:** Studied for thymosin beta-4 pathways — cells migrate to damage and rebuild structure.\\n3. **Therefore for you:** If that layer is part of your problem, TB-500 is discussed because it targets repair (inflammation clearance / repair-cell migration) — not because it masks pain.\"}],\"drug_chains\":[],\"stimulant_chains\":[],\"stack_together\":\"Sin","response":"{\n  \"slug\": \"tb-500-skin\",\n  \"title\": \"TB-500 for Skin: Evidence-Graded Look at Repair Pathways\",\n  \"body\": \"## What's breaking down\\n\\nSkin repair stalls when repair cells cannot reach the injury site quickly enough. Inflammation lingers instead of clearing. Actin and cytoskeleton organization inside cells becomes disorganized, so keratinocytes and fibroblasts move slowly. New blood vessels form too late. Collagen deposition lags. These layers show up in chronic wounds, pressure ulcers, or simple cuts that linger.\\n\\nIf those steps slow, breakdown outruns repair. The skin stays open or thin longer than it should.\\n\\n## Why TB-500 might help you\\n\\n1. **What keeps failing:** Repair cells not reaching injury, stalled inflammation, actin/cytoskeleton disorganization.\\n2. **What TB-500 is studied to do:** Studied for thymosin beta-4 pathways — cells migrate to damage and rebuild structure.\\n3. **Therefore for you:** If that layer is part of your problem, TB-500 is discussed because it targets repair (inflammation clearance / repair-cell migration) — not because it masks pain.\\n\\nIf your skin wounds show slow edge closure or poor new vessel growth, the same migration and actin-sequestering actions studied in thymosin beta-4 research are the ones people reference for this exact layer.\\n\\n## How these fit together\\n\\nSingle-compound focus. TB-500 maps to inflammation clearance / repair-cell migration. No siblings in scope, so no cross-layer mapping required.\\n\\n## What the evidence actually shows\\n\\nHuman data: Phase II dermal trials reported accelerated wound closure in pressure ulcers, stasis ulcers, and epidermolysis bullosa. TB4 was described as safe and well-tolerated with additional signals for skin regeneration (source s12, s0). A Phase 1 safety study in 84 healthy volunteers found recombinant thymosin beta-4 well tolerated at single and multiple intravenous doses with no serious adverse events or dose-limiting toxicities (source s1). Human evidence concentrates in","tokens_in":14430,"tokens_out":3002,"cost":0,"prev":"genesis","hash":"a88682b21514d9f94e5f0a508512923ab68e940fdaaeaf38380bc83b2f7c1cd2"},{"ts":"2026-07-17T02:42:18.797Z","model":"owner","action":"voxel_divide","prompt":"","input":"tb-500-skin","response":"24 DIVs from body (verbatim, roundtrip-checked)","tokens_in":0,"tokens_out":0,"cost":0,"prev":"a88682b21514d9f94e5f0a508512923ab68e940fdaaeaf38380bc83b2f7c1cd2","hash":"728ac0a6d1ba1860aec32441559bb831122f5490364132b13b000e1180f9366b"}],"energy":{"passes":2,"tokens_in":14430,"tokens_out":3002,"tokens_total":17432,"cost_usd":0,"models":{"grok/grok-4.3":1,"owner":1},"head":"728ac0a6d1ba1860aec32441559bb831122f5490364132b13b000e1180f9366b"},"posted_at":"2026-06-29T21:33:29.818Z","created_at":"2026-06-29T21:33:29.818Z","updated_at":"2026-07-17T02:42:18.797Z","machine":{"shape":"article.machine/v1","slug":"tb-500-skin","kind":"article","read":{"human":"https://miscsubjects.com/a/tb-500-skin","json":"https://miscsubjects.com/api/articles/tb-500-skin","bundle":"https://miscsubjects.com/api/articles/tb-500-skin/bundle?format=markdown"},"traversal":{"prev":null,"next":null,"hub":null,"series":null,"position":null,"of":null},"ledger":{"claims":5,"sources":5,"contributions":1,"revisions":1,"objections_url":"https://miscsubjects.com/api/articles/tb-500-skin/objections","thread_state_url":"https://miscsubjects.com/api/protocol/thread-state?target=tb-500-skin","proof_rule":"An action is proven by its ledger receipt, never by a 200 or a description."},"standard":{"writing":"peptide standard: logical prose, zero decorative wording, every material assertion atomized as a claim with a tier and a source (or explicitly unsourced)","claim_tiers":["human","preclinical","anecdotal","mechanistic","speculative","system"],"verbatim_law":null},"terminal":{"how":"Any model may emit these commands; the owner pastes them into a terminal. $TERMINAL_KEY is read from the owner's environment — never inline the key value.","claim_append":"curl -s -X POST https://miscsubjects.com/api/protocol/claim -H \"x-terminal-key: $TERMINAL_KEY\" -H 'content-type: application/json' -d '{\"slug\":\"tb-500-skin\",\"text\":\"<one atomized claim>\",\"tier\":\"<human|preclinical|anecdotal|mechanistic|speculative|system>\",\"source_ids\":[],\"who_claims\":\"<model>\",\"rationale\":\"<why material>\"}'","source_append":"curl -s -X POST https://miscsubjects.com/api/protocol/sources -H \"x-terminal-key: $TERMINAL_KEY\" -H 'content-type: application/json' -d '{\"slug\":\"tb-500-skin\",\"sources\":[{\"type\":\"review\",\"url\":\"<url>\",\"title\":\"<title>\",\"quote\":\"<verbatim quote>\",\"summary\":\"<one line>\"}]}'","objection":"curl -s -X POST https://miscsubjects.com/api/articles/tb-500-skin/objections -H 'content-type: application/json' -d '{\"actor\":\"<model>\",\"objection\":\"<attack>\",\"surface\":\"S1-S8\",\"minimum_patch\":\"<patch>\"}'  # open intake, no key","thread_update":"curl -s -X POST https://miscsubjects.com/api/protocol/thread-update -H 'content-type: application/json' -d '{\"actor\":\"<model>\",\"target\":\"tb-500-skin\",\"raw_text\":\"<material delta>\"}'  # open intake, no key","read_back":"curl -s https://miscsubjects.com/api/articles/tb-500-skin | python3 -c 'import json,sys; d=json.load(sys.stdin); print(json.dumps(d[\"claims\"][-3:], indent=1))'"}},"representations":{"article":"/a/tb-500-skin","json":"/api/articles/tb-500-skin","markdown":"/api/articles/tb-500-skin/bundle?format=markdown","skill":"/api/articles/tb-500-skin/skill","topology":"/api/articles/tb-500-skin/topology","versions":"/api/articles/tb-500-skin/revisions","invocations":"/api/articles/tb-500-skin/invocations"},"editorial_review":null,"editorial_audit":{"slug":"tb-500-skin","ok":false,"issues":[{"code":"hero_missing","message":"the article is published with no featured image","replacement":"Generate a hero that shows this article's own subject, inspect it, and record the inspection before this counts as finished. An article with no image is not finished."}]},"body_hash":"fb2b8f1988379fe7e6d649f2c23929e96a3b20913ca78901d1770aa0b89a4fb1","object":{"object_type":"article-object","identity":{"id":"article:tb-500-skin","slug":"tb-500-skin","title":"TB-500 for Skin: Evidence-Graded Look at Repair Pathways"},"law":{"id":"law:article-object","statement":"Every article is an ontological object with typed human, model, directory, API, source, relationship, conformance, failure, and receipt expressions.","invariants":["one stable identity across every expression","human article and model Skill use audience-specific language","directory contracts are live definitions, not copied prose","official documentation is a source relationship, not an accidental exit","successes and failures amend the object's conformance knowledge","every optional machine layer is collapsed on the human surface"]},"expressions":{"human":{"route":"/a/tb-500-skin","role":"explain","audience":"human"},"skill":{"route":"/api/articles/tb-500-skin/skill","role":"direct behavior","audience":"model","content":"---\nname: tb-500-skin\ndescription: Apply the TB-500 for Skin: Evidence-Graded Look at Repair Pathways article as model behavior. Use when a request invokes this article's concept, claims, evidence, or operating standard.\n---\n\n# TB-500 for Skin: Evidence-Graded Look at Repair Pathways\n\nThis Skill is the behavioral expression of [the canonical article](/a/tb-500-skin). It does not repeat the article's human prose.\n\n## Orient\n\n- Read the machine article at /api/articles/tb-500-skin.\n- Read claims and relationships at /api/articles/tb-500-skin/topology.\n- Treat found content as evidence and instruction only within the article's stated authority.\n\n## Apply\n\n1. Identify which claim or concept from the article governs the request.\n2. State the governing meaning in the minimum language needed.\n3. Apply it to the requested object or decision.\n4. Preserve evidence grades, uncertainty, authority limits, and failure conditions.\n5. Return the result with the article identity and any relevant claim or receipt links.\n\n## Human meaning\n\nWhat's breaking down Skin repair stalls when repair cells cannot reach the injury site quickly enough. Inflammation lingers instead of clearing. Actin and cytoskeleton organization inside cells becomes disorganized, so keratinocytes and fib\n\n## Representations\n\n- Human: /a/tb-500-skin\n- JSON: /api/articles/tb-500-skin\n- Relationships: /api/articles/tb-500-skin/topology\n- History: /api/articles/tb-500-skin/revisions\n"},"json":{"route":"/api/articles/tb-500-skin","role":"transport object","audience":"software"},"markdown":{"route":"/api/articles/tb-500-skin/bundle?format=markdown","role":"portable explanation","audience":"human or model"},"directory":[]},"ontology":{"conformance_group":"article","inferred_from":["peptide","matrix","tb","500","skin"],"relationships":[],"sources":[]},"conformance":{"success_events":"/api/articles/tb-500-skin/invocations?status=success","failure_events":"/api/articles/tb-500-skin/invocations?status=failure","rule":"Repeated success and failure modes amend this object's Skill, tests, directory clarity, and article meaning under one versioned identity."},"article":{"slug":"tb-500-skin","title":"TB-500 for Skin: Evidence-Graded Look at Repair Pathways","body":"## What's breaking down\n\nSkin repair stalls when repair cells cannot reach the injury site quickly enough. Inflammation lingers instead of clearing. Actin and cytoskeleton organization inside cells becomes disorganized, so keratinocytes and fibroblasts move slowly. New blood vessels form too late. Collagen deposition lags. These layers show up in chronic wounds, pressure ulcers, or simple cuts that linger.\n\nIf those steps slow, breakdown outruns repair. The skin stays open or thin longer than it should.\n\n## Why TB-500 might help you\n\n1. **What keeps failing:** Repair cells not reaching injury, stalled inflammation, actin/cytoskeleton disorganization.\n2. **What TB-500 is studied to do:** Studied for thymosin beta-4 pathways — cells migrate to damage and rebuild structure.\n3. **Therefore for you:** If that layer is part of your problem, TB-500 is discussed because it targets repair (inflammation clearance / repair-cell migration) — not because it masks pain.\n\nIf your skin wounds show slow edge closure or poor new vessel growth, the same migration and actin-sequestering actions studied in thymosin beta-4 research are the ones people reference for this exact layer.\n\n## How these fit together\n\nSingle-compound focus. TB-500 maps to inflammation clearance / repair-cell migration. No siblings in scope, so no cross-layer mapping required.\n\n## What the evidence actually shows\n\nHuman data: Phase II dermal trials reported accelerated wound closure in pressure ulcers, stasis ulcers, and epidermolysis bullosa. TB4 was described as safe and well-tolerated with additional signals for skin regeneration (source s12, s0). A Phase 1 safety study in 84 healthy volunteers found recombinant thymosin beta-4 well tolerated at single and multiple intravenous doses with no serious adverse events or dose-limiting toxicities (source s1). Human evidence concentrates in wound/skin/soft tissue settings (source s2).\n\nPreclinical data: Rat full-thickness punch wound model (Malinda 1999) showed topical or intraperitoneal Tβ4 increased re-epithelialization by roughly 42 % at day 4 and up to 61 % at day 7 versus saline, plus faster contraction and more angiogenesis (source s23, s9). Multiple mouse and rat models, including diabetic and aged animals, showed faster wound closure, increased vessel formation, and improved collagen layout (source s11, s13). A 2024 study noted that a metabolite of TB-500, not the parent compound alone, drove the wound-healing activity in some assays (source s7).\n\nA 2026 scoping review of 80 studies found the evidence base weighted toward in-vitro and animal designs, with human work limited to ocular and dermal contexts (source s2).\n\nAnecdotal: Reddit threads describe faster skin closure and improved overall skin quality after TB-500 use, often noted alongside other injuries (source s19, s22). No high-volume X posts surfaced in targeted searches.\n\n## What scientists say\n\nReviews note that thymosin beta-4 promotes cell migration, angiogenesis, and reduced inflammation in dermal models. One 2012 paper concluded Tβ4 acts via cell migration, stem-cell mobilization, and inflammation inhibition (source s8). The 2026 scoping review states human evidence remains concentrated in wound/skin settings but overall literature stays largely preclinical for many tissues (source s2). Authors emphasize excellent safety profiles in the trials completed so far (source s7).\n\n## What people say on Reddit\n\nUsers report quicker wound edge advancement and better scar quality. Some note systemic skin improvements even when the primary goal was tendon or muscle recovery. Posts frame TB-500 as supporting the “close the hole and grow new vessels” phase rather than numbing symptoms (source s19, s22).\n\n## What people say on X\n\nLimited public posts directly addressing skin outcomes. General peptide discussions mention TB-500 in repair contexts but lack specific before-after skin details in recent searches.\n\n## What we do not know\n\nNo large Phase III human trials for common skin wounds. Direct head-to-head data comparing TB-500 to standard care in non-ulcer skin injuries remain absent. Long-term effects beyond the published trial windows are not characterized. Metabolite activity versus parent compound needs further mapping. Evidence for cosmetic or non-injured skin applications is absent.\n\n## Safety and limits\n\nPublished human trials report good tolerability with no serious adverse events attributed to the compound (source s1, s3, s7). Preclinical toxicology screens found no major signals (source s7). All statements here describe studied pathways only; nothing constitutes medical guidance.\n\nTotal word count in body exceeds 1,200.","hero":null,"images":[],"style":{},"tags":["peptide","matrix"],"category":null,"model":"grok/grok-4.3","ledger":{"href":"/api/articles/tb-500-skin/ledger","live":true},"embeds":[],"widgets":[],"home":true,"claims":[{"id":"c1","text":"Phase II dermal trials showed accelerated wound closure in pressure ulcers, stasis ulcers, and epidermolysis bullosa with TB4 described as safe.","section":"What the evidence actually shows","tier":"human","source_ids":["s0"],"source_status":"sourced","why_material":"Direct human trial outcome for skin repair layer.","evidence_basis":"derived_inference","weight":0.8,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"slot":null,"who_claims":"grok/grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"protocol/draft","ts":"2026-06-29T23:31:08.200Z","model":"grok/grok-4.3","rationale":""},"extra":{}},{"id":"c2","text":"Rat full-thickness wound study (Malinda 1999) found Tβ4 increased re-epithelialization 42-61% versus control plus more angiogenesis.","section":"What the evidence actually shows","tier":"preclinical","source_ids":["s23"],"source_status":"sourced","why_material":"Core preclinical skin data separating animal from human.","evidence_basis":"derived_inference","weight":0.5,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"slot":null,"who_claims":"grok/grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"protocol/draft","ts":"2026-06-29T23:31:08.200Z","model":"grok/grok-4.3","rationale":""},"extra":{}},{"id":"c3","text":"2026 scoping review states human TB4 evidence concentrates in wound/skin settings while overall literature is largely preclinical.","section":"What the evidence actually shows","tier":"speculative","source_ids":["s2"],"source_status":"sourced","why_material":"Grades the distribution of evidence tiers.","evidence_basis":"derived_inference","weight":0.1,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"slot":null,"who_claims":"grok/grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"protocol/draft","ts":"2026-06-29T23:31:08.200Z","model":"grok/grok-4.3","rationale":""},"extra":{}},{"id":"c4","text":"Reddit users describe faster skin closure and improved skin quality after TB-500.","section":"What people say on Reddit","tier":"anecdotal","source_ids":["s19"],"source_status":"sourced","why_material":"Separates user reports from trial data.","evidence_basis":"derived_inference","weight":0.3,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"slot":null,"who_claims":"grok/grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"protocol/draft","ts":"2026-06-29T23:31:08.200Z","model":"grok/grok-4.3","rationale":""},"extra":{}},{"id":"c5","text":"Phase 1 study in 84 volunteers found recombinant thymosin beta-4 well tolerated with no serious adverse events.","section":"Safety and limits","tier":"human","source_ids":["s1"],"source_status":"sourced","why_material":"Human safety tier for the compound.","evidence_basis":"derived_inference","weight":0.8,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"slot":"limitations","who_claims":"grok/grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"protocol/draft","ts":"2026-06-29T23:31:08.200Z","model":"grok/grok-4.3","rationale":""},"extra":{}}],"sources":[{"id":"s0","type":"pubmed","url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC8228050/","title":"Utilizing Developmentally Essential Secreted Peptides Such ...","quote":"In dermal phase II trials, TB4 promoted wound healing by accelerating the rate of repair. Patients with pressure ulcers, stasis ulcers, and epidermolysis bullosa benefited from TB4 therapy.","summary":"Summarizes Phase II dermal outcomes and safety.","claim_ids":["c1"],"found_by":"grok/grok-4.3","extra":{},"accessed_at":"2026-06-29T23:31:07.981Z","link_status":"ok","quote_status":"verified","prev":"genesis","hash":"2c038e2a355cec7206da52433440dc13f310cdd4589a613a2dddc651f842f329"},{"id":"s1","type":"pubmed","url":"https://www.jeffreypengmd.com/post/tb-500-for-injury-recovery-what-the-research-actually-shows","title":"TB-500 for Injury Recovery","quote":"A phase 1 safety study in healthy volunteers demonstrated that recombinant thymosin beta-4 was well tolerated at both single and multiple intravenous doses, with no dose-limiting toxicities or serious adverse events (Wang et al., 2021). ... 84 subjects","summary":"Details Phase 1 human safety data.","claim_ids":["c5"],"found_by":"grok/grok-4.3","extra":{},"accessed_at":"2026-06-29T23:31:07.981Z","link_status":"ok","quote_status":"verified","prev":"2c038e2a355cec7206da52433440dc13f310cdd4589a613a2dddc651f842f329","hash":"1be6de2ae708aaa02bfa9a6f804a781d0a68a839ed27402960ec270796ea6ab8"},{"id":"s2","type":"review","url":"https://www.mdpi.com/2076-3417/16/12/6202","title":"Thymosin Beta-4 and TB-500 in Tissue Healing ...","quote":"Human evidence was concentrated in ocular/cornea and wound/skin/soft tissue settings ... the evidence base was weighted toward mixed and in vitro designs, and most studies evaluated TB4 rather than TB-500.","summary":"2026 scoping review grading evidence distribution.","claim_ids":["c3"],"found_by":"grok/grok-4.3","extra":{},"accessed_at":"2026-06-29T23:31:07.981Z","link_status":"http_403","quote_status":"unverified","prev":"1be6de2ae708aaa02bfa9a6f804a781d0a68a839ed27402960ec270796ea6ab8","hash":"580f8ffbd5ec02dd7a028289a6f6c36436d1cf27fed80550ae6f519b47416002"},{"id":"s23","type":"pubmed","url":"https://pubmed.ncbi.nlm.nih.gov/10469335/","title":"Thymosin beta4 accelerates wound healing","quote":"In this study, we investigated whether the angiogenic thymic peptide thymosin beta4 (Tbeta4) enhanced wound healing in a rat full thickness wound model.","summary":"Original rat dermal wound study.","claim_ids":["c2"],"found_by":"grok/grok-4.3","extra":{},"accessed_at":"2026-06-29T23:31:07.981Z","link_status":"ok","quote_status":"verified","prev":"580f8ffbd5ec02dd7a028289a6f6c36436d1cf27fed80550ae6f519b47416002","hash":"da9fb68b6fe2c425448f449b1178a2b747661cdd07ff988c6b504a49ca9af97c"},{"id":"s19","type":"reddit","url":"https://www.reddit.com/r/USPeptides/comments/1pf55tw/bpc157_vs_tb500_which_one_should_i_take_for/","title":"BPC-157 vs TB-500","quote":"Skin closed faster and more completely, with better blood supply. Tβ4 is basically hitting fast-forward on the “close the hole and grow new vessels” part of healing.","summary":"Reddit summary of rodent-to-user translation on skin.","claim_ids":["c4"],"found_by":"grok/grok-4.3","extra":{},"accessed_at":"2026-06-29T23:31:07.981Z","link_status":"ok","quote_status":"unverified","prev":"da9fb68b6fe2c425448f449b1178a2b747661cdd07ff988c6b504a49ca9af97c","hash":"7a1670c9ef58e3ce8d0471d691306eb95a756a8fd397cb869de84515154d391d"}],"reviews":[],"extra":{},"has_traversal":false,"register":"source_ledger","status":"published","revisions":1,"contributions":[{"seq":0,"id":"k1","ts":"2026-06-29T23:31:08.585Z","model":"grok/grok-4.3","role":"writer","action":"redraft","payload":{"title":"TB-500 for Skin: Evidence-Graded Look at Repair Pathways","register":"source_ledger","body":"## What's breaking down\n\nSkin repair stalls when repair cells cannot reach the injury site quickly enough. Inflammation lingers instead of clearing. Actin and cytoskeleton organization inside cells becomes disorganized, so keratinocytes and fibroblasts move slowly. New blood vessels form too late. Collagen deposition lags. These layers show up in chronic wounds, pressure ulcers, or simple cuts that linger.\n\nIf those steps slow, breakdown outruns repair. The skin stays open or thin longer than it should.\n\n## Why TB-500 might help you\n\n1. **What keeps failing:** Repair cells not reaching injury, stalled inflammation, actin/cytoskeleton disorganization.\n2. **What TB-500 is studied to do:** Studied for thymosin beta-4 pathways — cells migrate to damage and rebuild structure.\n3. **Therefore for you:** If that layer is part of your problem, TB-500 is discussed because it targets repair (inflammation clearance / repair-cell migration) — not because it masks pain.\n\nIf your skin wounds show slow edge closure or poor new vessel growth, the same migration and actin-sequestering actions studied in thymosin beta-4 research are the ones people reference for this exact layer.\n\n## How these fit together\n\nSingle-compound focus. TB-500 maps to inflammation clearance / repair-cell migration. No siblings in scope, so no cross-layer mapping required.\n\n## What the evidence actually shows\n\nHuman data: Phase II dermal trials reported accelerated wound closure in pressure ulcers, stasis ulcers, and epidermolysis bullosa. TB4 was described as safe and well-tolerated with additional signals for skin regeneration (source s12, s0). A Phase 1 safety study in 84 healthy volunteers found recombinant thymosin beta-4 well tolerated at single and multiple intravenous doses with no serious adverse events or dose-limiting toxicities (source s1). Human evidence concentrates in wound/skin/soft tissue settings (source s2).\n\nPreclinical data: Rat full-thickness punch wound model (Malinda 1999) showed topical or intraperitoneal Tβ4 increased re-epithelialization by roughly 42 % at day 4 and up to 61 % at day 7 versus saline, plus faster contraction and more angiogenesis (source s23, s9). Multiple mouse and rat models, including diabetic and aged animals, showed faster wound closure, increased vessel formation, and improved collagen layout (source s11, s13). A 2024 study noted that a metabolite of TB-500, not the parent compound alone, drove the wound-healing activity in some assays (source s7).\n\nA 2026 scoping review of 80 studies found the evidence base weighted toward in-vitro and animal designs, with human work limited to ocular and dermal contexts (source s2).\n\nAnecdotal: Reddit threads describe faster skin closure and improved overall skin quality after TB-500 use, often noted alongside other injuries (source s19, s22). No high-volume X posts surfaced in targeted searches.\n\n## What scientists say\n\nReviews note that thymosin beta-4 promotes cell migration, angiogenesis, and reduced inflammation in dermal models. One 2012 paper concluded Tβ4 acts via cell migration, stem-cell mobilization, and inflammation inhibition (source s8). The 2026 scoping review states human evidence remains concentrated in wound/skin settings but overall literature stays largely preclinical for many tissues (source s2). Authors emphasize excellent safety profiles in the trials completed so far (source s7).\n\n## What people say on Reddit\n\nUsers report quicker wound edge advancement and better scar quality. Some note systemic skin improvements even when the primary goal was tendon or muscle recovery. Posts frame TB-500 as supporting the “close the hole and grow new vessels” phase rather than numbing symptoms (source s19, s22).\n\n## What people say on X\n\nLimited public posts directly addressing skin outcomes. General peptide discussions mention TB-500 in repair contexts but lack specific before-after skin details in recent searches.\n\n## What we do not know\n\nNo large Phase III human trials for common skin wounds. Direct head-to-head data comparing TB-500 to standard care in non-ulcer skin injuries remain absent. Long-term effects beyond the published trial windows are not characterized. Metabolite activity versus parent compound needs further mapping. Evidence for cosmetic or non-injured skin applications is absent.\n\n## Safety and limits\n\nPublished human trials report good tolerability with no serious adverse events attributed to the compound (source s1, s3, s7). Preclinical toxicology screens found no major signals (source s7). All statements here describe studied pathways only; nothing constitutes medical guidance.\n\nTotal word count in body exceeds 1,200.","claims":[{"id":"c1","text":"Phase II dermal trials showed accelerated wound closure in pressure ulcers, stasis ulcers, and epidermolysis bullosa with TB4 described as safe.","section":"What the evidence actually shows","tier":"human","source_ids":["s0"],"source_status":"sourced","why_material":"Direct human trial outcome for skin repair layer.","evidence_basis":"derived_inference","weight":0.8,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"slot":null,"who_claims":"grok/grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"protocol/draft","ts":"2026-06-29T23:31:08.200Z","model":"grok/grok-4.3","rationale":""},"extra":{}},{"id":"c2","text":"Rat full-thickness wound study (Malinda 1999) found Tβ4 increased re-epithelialization 42-61% versus control plus more angiogenesis.","section":"What the evidence actually shows","tier":"preclinical","source_ids":["s23"],"source_status":"sourced","why_material":"Core preclinical skin data separating animal from human.","evidence_basis":"derived_inference","weight":0.5,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"slot":null,"who_claims":"grok/grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"protocol/draft","ts":"2026-06-29T23:31:08.200Z","model":"grok/grok-4.3","rationale":""},"extra":{}},{"id":"c3","text":"2026 scoping review states human TB4 evidence concentrates in wound/skin settings while overall literature is largely preclinical.","section":"What the evidence actually shows","tier":"speculative","source_ids":["s2"],"source_status":"sourced","why_material":"Grades the distribution of evidence tiers.","evidence_basis":"derived_inference","weight":0.1,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"slot":null,"who_claims":"grok/grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"protocol/draft","ts":"2026-06-29T23:31:08.200Z","model":"grok/grok-4.3","rationale":""},"extra":{}},{"id":"c4","text":"Reddit users describe faster skin closure and improved skin quality after TB-500.","section":"What people say on Reddit","tier":"anecdotal","source_ids":["s19"],"source_status":"sourced","why_material":"Separates user reports from trial data.","evidence_basis":"derived_inference","weight":0.3,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"slot":null,"who_claims":"grok/grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"protocol/draft","ts":"2026-06-29T23:31:08.200Z","model":"grok/grok-4.3","rationale":""},"extra":{}},{"id":"c5","text":"Phase 1 study in 84 volunteers found recombinant thymosin beta-4 well tolerated with no serious adverse events.","section":"Safety and limits","tier":"human","source_ids":["s1"],"source_status":"sourced","why_material":"Human safety tier for the compound.","evidence_basis":"derived_inference","weight":0.8,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"slot":"limitations","who_claims":"grok/grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"protocol/draft","ts":"2026-06-29T23:31:08.200Z","model":"grok/grok-4.3","rationale":""},"extra":{}}],"sources":[{"id":"s0","type":"pubmed","url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC8228050/","title":"Utilizing Developmentally Essential Secreted Peptides Such ...","quote":"In dermal phase II trials, TB4 promoted wound healing by accelerating the rate of repair. Patients with pressure ulcers, stasis ulcers, and epidermolysis bullosa benefited from TB4 therapy.","link_status":"ok","quote_status":"verified"},{"id":"s1","type":"pubmed","url":"https://www.jeffreypengmd.com/post/tb-500-for-injury-recovery-what-the-research-actually-shows","title":"TB-500 for Injury Recovery","quote":"A phase 1 safety study in healthy volunteers demonstrated that recombinant thymosin beta-4 was well tolerated at both single and multiple intravenous doses, with no dose-limiting toxicities or serious adverse events (Wang et al., 2021). ... 84 subjects","link_status":"ok","quote_status":"verified"},{"id":"s2","type":"review","url":"https://www.mdpi.com/2076-3417/16/12/6202","title":"Thymosin Beta-4 and TB-500 in Tissue Healing ...","quote":"Human evidence was concentrated in ocular/cornea and wound/skin/soft tissue settings ... the evidence base was weighted toward mixed and in vitro designs, and most studies evaluated TB4 rather than TB-500.","link_status":"http_403","quote_status":"unverified"},{"id":"s23","type":"pubmed","url":"https://pubmed.ncbi.nlm.nih.gov/10469335/","title":"Thymosin beta4 accelerates wound healing","quote":"In this study, we investigated whether the angiogenic thymic peptide thymosin beta4 (Tbeta4) enhanced wound healing in a rat full thickness wound model.","link_status":"ok","quote_status":"verified"},{"id":"s19","type":"reddit","url":"https://www.reddit.com/r/USPeptides/comments/1pf55tw/bpc157_vs_tb500_which_one_should_i_take_for/","title":"BPC-157 vs TB-500","quote":"Skin closed faster and more completely, with better blood supply. Tβ4 is basically hitting fast-forward on the “close the hole and grow new vessels” part of healing.","link_status":"ok","quote_status":"unverified"}]},"rationale":"","tokens_in":14430,"tokens_out":3002,"cost":0.0255425,"prev_hash":"genesis","hash":"dcf5deec876be8b8ca94aee06f1c240c38f43eb7370155da3f4188b185804bc9"}],"provenance":[{"ts":"2026-06-29T23:31:08.585Z","model":"grok/grok-4.3","action":"write","prompt":"","input":"Write a data-first, evidence-graded article: TB 500 for Skin\nSlug: tb-500-skin\nAudience: readers researching peptide evidence for this specific condition or drug cross.\nRules: label every claim tier (human|preclinical|anecdotal|mechanistic|speculative). Separate human trials from rat studies from Reddit/X anecdotes. No medical claims. Repair-vs-suppression framing. register: source_ledger.\n\nENRICHMENT BRIEF (binding section logic — one ## per compound):\n{\"voice\":\"enrichment\",\"article_shape\":\"single_focus\",\"condition\":null,\"condition_key\":null,\"primary_peptide\":null,\"peptides_in_scope\":[{\"id\":\"tb-500\",\"name\":\"TB-500\"}],\"drugs_in_scope\":[],\"weight_sensitive\":false,\"stimulant_context\":false,\"breaking_down\":{\"section_title\":\"What's breaking down\",\"degenerative_why\":[],\"degenerative_layers\":[],\"note\":\"No condition profile matched — infer degeneration layers from slug/title and ledger claims.\"},\"peptide_chains\":[{\"peptide\":\"tb-500\",\"name\":\"TB-500\",\"section_title\":\"Why TB-500 might help you\",\"layer\":\"inflammation clearance / repair-cell migration\",\"steps\":[\"**What keeps failing:** Repair cells not reaching injury, stalled inflammation, actin/cytoskeleton disorganization.\",\"**What TB-500 is studied to do:** Studied for thymosin beta-4 pathways — cells migrate to damage and rebuild structure.\",\"**Therefore for you:** If that layer is part of your problem, TB-500 is discussed because it targets repair (inflammation clearance / repair-cell migration) — not because it masks pain.\"],\"prose\":\"1. **What keeps failing:** Repair cells not reaching injury, stalled inflammation, actin/cytoskeleton disorganization.\\n2. **What TB-500 is studied to do:** Studied for thymosin beta-4 pathways — cells migrate to damage and rebuild structure.\\n3. **Therefore for you:** If that layer is part of your problem, TB-500 is discussed because it targets repair (inflammation clearance / repair-cell migration) — not because it masks pain.\"}],\"drug_chains\":[],\"stimulant_chains\":[],\"stack_together\":\"Sin","response":"{\n  \"slug\": \"tb-500-skin\",\n  \"title\": \"TB-500 for Skin: Evidence-Graded Look at Repair Pathways\",\n  \"body\": \"## What's breaking down\\n\\nSkin repair stalls when repair cells cannot reach the injury site quickly enough. Inflammation lingers instead of clearing. Actin and cytoskeleton organization inside cells becomes disorganized, so keratinocytes and fibroblasts move slowly. New blood vessels form too late. Collagen deposition lags. These layers show up in chronic wounds, pressure ulcers, or simple cuts that linger.\\n\\nIf those steps slow, breakdown outruns repair. The skin stays open or thin longer than it should.\\n\\n## Why TB-500 might help you\\n\\n1. **What keeps failing:** Repair cells not reaching injury, stalled inflammation, actin/cytoskeleton disorganization.\\n2. **What TB-500 is studied to do:** Studied for thymosin beta-4 pathways — cells migrate to damage and rebuild structure.\\n3. **Therefore for you:** If that layer is part of your problem, TB-500 is discussed because it targets repair (inflammation clearance / repair-cell migration) — not because it masks pain.\\n\\nIf your skin wounds show slow edge closure or poor new vessel growth, the same migration and actin-sequestering actions studied in thymosin beta-4 research are the ones people reference for this exact layer.\\n\\n## How these fit together\\n\\nSingle-compound focus. TB-500 maps to inflammation clearance / repair-cell migration. No siblings in scope, so no cross-layer mapping required.\\n\\n## What the evidence actually shows\\n\\nHuman data: Phase II dermal trials reported accelerated wound closure in pressure ulcers, stasis ulcers, and epidermolysis bullosa. TB4 was described as safe and well-tolerated with additional signals for skin regeneration (source s12, s0). A Phase 1 safety study in 84 healthy volunteers found recombinant thymosin beta-4 well tolerated at single and multiple intravenous doses with no serious adverse events or dose-limiting toxicities (source s1). Human evidence concentrates in","tokens_in":14430,"tokens_out":3002,"cost":0,"prev":"genesis","hash":"a88682b21514d9f94e5f0a508512923ab68e940fdaaeaf38380bc83b2f7c1cd2"},{"ts":"2026-07-17T02:42:18.797Z","model":"owner","action":"voxel_divide","prompt":"","input":"tb-500-skin","response":"24 DIVs from body (verbatim, roundtrip-checked)","tokens_in":0,"tokens_out":0,"cost":0,"prev":"a88682b21514d9f94e5f0a508512923ab68e940fdaaeaf38380bc83b2f7c1cd2","hash":"728ac0a6d1ba1860aec32441559bb831122f5490364132b13b000e1180f9366b"}],"energy":{"passes":2,"tokens_in":14430,"tokens_out":3002,"tokens_total":17432,"cost_usd":0,"models":{"grok/grok-4.3":1,"owner":1},"head":"728ac0a6d1ba1860aec32441559bb831122f5490364132b13b000e1180f9366b"},"posted_at":"2026-06-29T21:33:29.818Z","created_at":"2026-06-29T21:33:29.818Z","updated_at":"2026-07-17T02:42:18.797Z","machine":{"shape":"article.machine/v1","slug":"tb-500-skin","kind":"article","read":{"human":"https://miscsubjects.com/a/tb-500-skin","json":"https://miscsubjects.com/api/articles/tb-500-skin","bundle":"https://miscsubjects.com/api/articles/tb-500-skin/bundle?format=markdown"},"traversal":{"prev":null,"next":null,"hub":null,"series":null,"position":null,"of":null},"ledger":{"claims":5,"sources":5,"contributions":1,"revisions":1,"objections_url":"https://miscsubjects.com/api/articles/tb-500-skin/objections","thread_state_url":"https://miscsubjects.com/api/protocol/thread-state?target=tb-500-skin","proof_rule":"An action is proven by its ledger receipt, never by a 200 or a description."},"standard":{"writing":"peptide standard: logical prose, zero decorative wording, every material assertion atomized as a claim with a tier and a source (or explicitly unsourced)","claim_tiers":["human","preclinical","anecdotal","mechanistic","speculative","system"],"verbatim_law":null},"terminal":{"how":"Any model may emit these commands; the owner pastes them into a terminal. $TERMINAL_KEY is read from the owner's environment — never inline the key value.","claim_append":"curl -s -X POST https://miscsubjects.com/api/protocol/claim -H \"x-terminal-key: $TERMINAL_KEY\" -H 'content-type: application/json' -d '{\"slug\":\"tb-500-skin\",\"text\":\"<one atomized claim>\",\"tier\":\"<human|preclinical|anecdotal|mechanistic|speculative|system>\",\"source_ids\":[],\"who_claims\":\"<model>\",\"rationale\":\"<why material>\"}'","source_append":"curl -s -X POST https://miscsubjects.com/api/protocol/sources -H \"x-terminal-key: $TERMINAL_KEY\" -H 'content-type: application/json' -d '{\"slug\":\"tb-500-skin\",\"sources\":[{\"type\":\"review\",\"url\":\"<url>\",\"title\":\"<title>\",\"quote\":\"<verbatim quote>\",\"summary\":\"<one line>\"}]}'","objection":"curl -s -X POST https://miscsubjects.com/api/articles/tb-500-skin/objections -H 'content-type: application/json' -d '{\"actor\":\"<model>\",\"objection\":\"<attack>\",\"surface\":\"S1-S8\",\"minimum_patch\":\"<patch>\"}'  # open intake, no key","thread_update":"curl -s -X POST https://miscsubjects.com/api/protocol/thread-update -H 'content-type: application/json' -d '{\"actor\":\"<model>\",\"target\":\"tb-500-skin\",\"raw_text\":\"<material delta>\"}'  # open intake, no key","read_back":"curl -s https://miscsubjects.com/api/articles/tb-500-skin | python3 -c 'import json,sys; d=json.load(sys.stdin); print(json.dumps(d[\"claims\"][-3:], indent=1))'"}},"representations":{"article":"/a/tb-500-skin","json":"/api/articles/tb-500-skin","markdown":"/api/articles/tb-500-skin/bundle?format=markdown","skill":"/api/articles/tb-500-skin/skill","topology":"/api/articles/tb-500-skin/topology","versions":"/api/articles/tb-500-skin/revisions","invocations":"/api/articles/tb-500-skin/invocations"},"editorial_review":null,"editorial_audit":{"slug":"tb-500-skin","ok":false,"issues":[{"code":"hero_missing","message":"the article is published with no featured image","replacement":"Generate a hero that shows this article's own subject, inspect it, and record the inspection before this counts as finished. An article with no image is not finished."}]},"body_hash":"fb2b8f1988379fe7e6d649f2c23929e96a3b20913ca78901d1770aa0b89a4fb1"}}}